Hillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13
July 08 2022 - 7:17AM
Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the
“Company”), a biotechnology company developing novel therapeutic
candidates targeting ferroptosis, an emerging new anti-cancer
mechanism resulting in iron mediated cell death for drug resistant
and devastating cancers, will attend the 12th Annual World Orphan
Drug Congress USA 2022, being held at the Hynes Convention Center
in Boston, on July 11-13, 2022.
Mr. Randy Milby, Founder and Chief Executive Officer of
Hillstream BioPharma will meet with a broad scope of patient
advocates, scientists, and executives in the rare disease ecosystem
to assist in the development and commercialization of the Company’s
signature cancer fighting treatments.
“We look forward to the opportunity to attend this premiere
event to network and connect with people and organizations that are
focused solely on transforming ways to advance orphan drug
development and improve access to life saving therapies,” said Mr.
Milby. “We continue to market our novel therapeutic products we are
developing to gain exposure within the medical and healthcare
system and take necessary steps to enhance the success of our
game-changing cancer treatment.”
To schedule a meeting with Mr. Randy Milby, please email
investorrelations@hillstreambio.com.
About World Orphan Drug Congress USA 2022The
12th Annual World Orphan Drug Congress USA 2022 will have over
1,700 attendees, from 50+ countries, and will take place in Boston,
MA at the Hynes Convention Center on July 11-13, 2022. The past
conferences have been held in Washington, DC, but due to the
popularity and growth of the annual event, the venue has changed to
a larger location. Since its inception in 2010, The World Orphan
Drug Congress has solidified its position as the largest, rare
disease and orphan drug conference, globally. Over 3 days,
attendees will have the opportunity to hear from 250+ speakers
across our 13 themes of content, engage in networking opportunities
and customize the experience at the congress. This conference
attracts the entire rare disease ecosystem – breaking down silos
and fostering collaboration to help rare disease patients. The
leading orphan drug pharmaceutical and biotech companies,
government and regulatory authorities, patient advocacy groups,
payers, investors and solution providers rely on the congress to
meet and brainstorm ways to advance orphan drug development and
improve access to life-saving therapies. For more information,
please visit:
https://www.terrapinn.com/conference/world-orphan-drug-congress-usa/index.stm.
About Hillstream BioPharma Inc.Hillstream
BioPharma, Inc. is a biotechnology company developing novel
therapeutic candidates targeting ferroptosis, an emerging new
anti-cancer mechanism resulting in iron mediated cell death for
drug resistant and devastating cancers. Hillstream’s most advanced
candidate is HSB-1216, an IMCD modulator, targeting a variety of
solid tumors. The active drug in HSB-1216 was found to be
efficacious in a clinical pilot study in Germany in devastating
cancers, including triple negative breast cancer and epithelial
carcinomas. Hillstream intends to start a clinical study with
HSB-1216 in 2022 to expand upon the existing early clinical
proof-of-concept. Hillstream uses Quatramer™, our proprietary tumor
targeting platform, to enhance the uptake of HSB-1216 in the tumor
microenvironment with an extended duration of action and minimal
off-target toxicity. In addition, Trident Artificial Intelligence,
Hillstream’s artificial intelligence precision medicine platform,
is used to identify biomarkers in our clinical programs to target a
specific patient segment most likely to benefit. For more
information, please visit www.hillstreambio.com.
Forward Looking StatementsCertain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified using words such as “anticipate,” “believe,”
“forecast,” “estimated” and “intend” or other similar terms or
expressions that concern Hillstream’s expectations, strategy, plans
or intentions. These forward-looking statements are based on
Hillstream’s current expectations and actual results could differ
materially. There are several factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, clinical trials involve a lengthy and expensive process
with an uncertain outcome, and results of earlier studies and
trials may not be predictive of future trial results; our clinical
trials may be suspended or discontinued due to unexpected side
effects or other safety risks that could preclude approval of our
product candidates; risks related to business interruptions,
including the outbreak of COVID-19 coronavirus, which could
seriously harm our financial condition and increase our costs and
expenses; dependence on key personnel; substantial competition;
uncertainties of patent protection and litigation; dependence upon
third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations.
Investors should read the risk factors set forth in our Form 10-K
for the year ended December 31, 2021 and our periodic reports filed
with the Securities and Exchange Commission. While the list of
factors presented here is considered representative, no such list
should be considered to be a complete statement of all potential
risks and uncertainties. Unlisted factors may present significant
additional obstacles to the realization of forward-looking
statements. Forward-looking statements included herein are made as
of the date hereof, and Hillstream does not undertake any
obligation to update publicly such statements to reflect subsequent
events or circumstances.
Investor Relations
Contact:Email: investorrelations@hillstreambio.comwww.hillstreambio.com
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Apr 2024 to May 2024
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From May 2023 to May 2024